On 2/13/2020, the U.S. Food and Drug Administration (FDA) requested that the manufacturer of lorcaserin (Belviq) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
- TRADE NAME: Belviq (Eisai)
- INDICATIONS: Obesity in adults who have at least one weight-related health condition, such as high blood pressure, Type II diabetes, or high cholesterol
- CLASS: Anti-obesity / weight loss pharmacotherapy, Serotonin receptor agonist
- HALF-LIFE: ~11 hours
- FDA APPROVAL DATE: 06/27/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antipsychotics, Bupropion, Dextromethorphan, Lithium, MAO inhibitors, SNRIs, SSRIs, St John's Wort, Tramadol, Tricyclic antidepressants, Triptans
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/28/2025
